Renalytix earnings date
Renalytix (2O9) Q3 2024 Earnings Report
DE:2O9 Q3 2024 EPS Results
- Actual EPS
- -EUR 0.04
- Consensus EPS
- -EUR 0.04
- Beat/Miss
- Beat by +EUR 0.00
- One Year Ago EPS
- -EUR 0.06
DE:2O9 Q3 2024 Revenue Results
- Actual Revenue
- EUR 506.83K
- Expected Revenue
- EUR 991.41K
- Beat/Miss
- Missed by -EUR 484.58K
- YoY Revenue Growth
- -29.19%
Earnings Announcement Details
- Quarter
- Q3 2024
- Date
- 05/15/2024
- Time
- Before Open
- Conference Call
- Wednesday, May 15, 2024
Renalytix's next earnings date is estimated for December 8, 2026, based on past reporting schedules.
Q3 2024 Earnings Call Audio
Q3 2024 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2024 Earnings Call Summary
The earnings call highlighted significant strategic achievements, including Medicare coverage developments, inclusion in clinical guidelines, successful fundraising, and cost reduction efforts. However, there are challenges such as a decline in revenue and testing volumes, and adoption hurdles in the VA system. The sentiment is balanced, with positive long-term strategic developments countered by short-term operational challenges.
During the third quarter earnings call for Renalytix (Symbol: RENX.L), management provided a detailed overview of their financial and strategic progress. The company reported a revenue of $535,000 for Q3 2024, with 806 tests processed, 82% of which were billable. This reflects a decline from the previous year, attributed to the conclusion of a $6 million contract with Mount Sinai. Operating expenses were significantly reduced by 40% year-over-year to $6.5 million, following strategic reorganization efforts, including a 50% reduction in headcount. The net loss also decreased by 36% to $7.7 million. The launch of the FDA-authorized KidneyIntelX.dkd product and increased insurance reimbursement were highlighted as key developments. The company emphasized their strategic focus on sales growth with a 33% increase in direct-to-physician test orders quarter-over-quarter, while anticipating further growth with the expected finalization of Medicare coverage and inclusion in international clinical guidelines. Additionally, Renalytix raised $13.5 million in aggregate gross proceeds from recent financings and reported $4.7 million in cash as of March 31, excluding additional financing proceeds. The ongoing strategic review, including potential acquisition interest, was also discussed, though specifics were limited due to regulatory constraints.
- Positive Medicare Coverage DevelopmentsMedicare contractor National Government Services issued a draft local coverage determination for KidneyIntelX, with expectations for a final coverage determination in the near term.
- Inclusion in International Clinical GuidelinesKidneyIntelX was included in the KDIGO international clinical guidelines for chronic kidney disease, marking a significant milestone for broader adoption.
- Successful FundraisingCompleted common stock equity financing rounds in March and April, raising net proceeds of approximately $13.5 million, extending the financial runway.
- FDA-Authorized Product LaunchLaunched the FDA-authorized KidneyIntelX.dkd product version, with commercial test orders now being received.
- Cost Reduction AchievementsYear-over-year headcount reduction of 50% and overall operating expenses reduced by approximately 40%, aiming for further expense reductions.
- Direct-to-Physician Sales GrowthAchieved a 33% increase in direct-to-primary-care test order rates quarter-over-quarter, indicating early growth trends.
- Strategic Acquisition InterestReceived interest from multiple potential acquirers, with a competitive sale process anticipated.
DE:2O9 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Dec 08, 2026 | 2027 (Q1) | ―- | ― | ― | ― |
| Oct 28, 2026 | 2026 (Q4) | ―-0.01 | ― | ― | |
| Mar 26, 2026 | 2026 (Q2) | ―-0.02 | -0.06 | 68.00% (+0.04) | |
| Nov 26, 2025 | 2026 (Q1) | ―- | -0.04 | ― | |
| Nov 03, 2025 | 2025 (Q4) | ―- | -0.04 | ― | |
| Jun 17, 2025 | 2025 (Q3) | ―- | -0.1 | ― | |
| Mar 18, 2025 | 2025 (Q2) | ―-0.05 | -0.04 | -11.11% (-0.00) | |
| Nov 20, 2024 | 2025 (Q1) | ―- | -0.05 | ― | |
| Oct 01, 2024 | 2024 (Q4) | -0.02-0.04 | -0.05 | 27.27% (+0.01) | |
| May 15, 2024 | 2024 (Q3) | -0.04-0.04 | -0.06 | 42.86% (+0.03) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

